The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series
Isabelle Koné‐Paut(Université Paris-Saclay), Maryam Piram(Université Paris-Saclay), Rolando Cimaz(University of Milan), Maria Cristina Maggio(University of Palermo), Jethro Herberg(Imperial College London), Jean Pierre Saulnier(Centre Hospitalier Universitaire de Poitiers), Oliver Bates(Imperial College London), Aurélia Carbasse(Centre Hospitalier Universitaire de Montpellier), Jordi Antón
Cited by 129
Related Papers
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
|The Lancet Respiratory Medicine|2014|648
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
|Frontiers in Pharmacology|2019|616
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients
|Arthritis & Rheumatology|2014|430
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease
|Nature Genetics|2011|355